CD274 and squamous cell carcinoma: In the KEYNOTE-567 trial, the combination with DNA vaccination with pembrolizumab showed a better response in patients with PD-L1-positive, HPV-16, and squamous cell carcinoma than pembrolizumab alone (NCT03444376) [80].